|
【结 构 式】 
|
【分子编号】50622 【品名】(2S)-6-amino-2-[((2S)-2-[[(benzyloxy)carbonyl]amino]-4-sulfanylbutanoyl)amino]hexanoic acid 【CA登记号】 |
【 分 子 式 】C18H27N3O5S 【 分 子 量 】397.4956 【元素组成】C 54.39% H 6.85% N 10.57% O 20.13% S 8.07% |
合成路线1
该中间体在本合成路线中的序号：(VII)The activation of N,N'-bis(benzyloxycarbonyl)-L-homocystine (I) with N-hydroxysuccinimide (II) by means of DCC gives the activated diester (III), which is condensed with N-(tert-butoxycarbonyl)-L-lysine (IV) by means of K2CO3, yielding the protected peptide (V). The selective deprotection of the epsilon amino groups of (V) by means of formic acid affords the dimeric peptide (VI), which is cleaved with dithiothreitol (DTT) to provide benzyloxycarbonyl-L-homocysteinyl-L-lysine (VII). The oxidation of (VII) with L-lysine epsilon aminotransferase (S. paucimobili or rec. E. coli) furnishes the formyl derivative (VIII), which is finally cyclized in acid medium to afford, through the nonisolated intermediate (IX), the target pyrido[2,1-b][1,3]thiazepine intermediate (X).
| 【1】 Patel, R.N.; Enzymatic synthesis of chiral intermediates for omapatrilat, an antihypertensive drug. Biomol Eng 2001, 17, 6, 167. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 50614 | (2S)-2-[[(benzyloxy)carbonyl]amino]-4-[((3S)-3-[[(benzyloxy)carbonyl]amino]-3-carboxypropyl)disulfanyl]butyric acid | C24H28N2O8S2 | 详情 | 详情 | |
| (II) | 10264 | 1-Hydroxydihydro-1H-pyrrole-2,5-dione; N-Hydroxysuccinimide; 1-Hydroxy-2,5-pyrrolidinedione | 6066-82-6 | C4H5NO3 | 详情 | 详情 |
| (III) | 50618 | benzyl (1S)-3-([(3S)-3-[[(benzyloxy)carbonyl]amino]-4-[(2,5-dioxo-1-pyrrolidinyl)oxy]-4-oxobutyl]disulfanyl)-1-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]propylcarbamate | C32H34N4O12S2 | 详情 | 详情 | |
| (IV) | 50619 | N(epsilon)-Boc-L-lysine | C11H22N2O4 | 详情 | 详情 | |
| (V) | 50620 | (10S,13S,20S,23S)-13,20-bis[[(benzyloxy)carbonyl]amino]-23-[4-[(tert-butoxycarbonyl)amino]butyl]-10-carboxy-2,2-dimethyl-4,12,21-trioxo-3-oxa-16,17-dithia-5,11,22-triazatetracosan-24-oic acid | C46H68N6O14S2 | 详情 | 详情 | |
| (VI) | 50621 | (5S,12S,15S)-15-(4-aminobutyl)-5-([[(1S)-5-amino-1-carboxypentyl]amino]carbonyl)-12-[[(benzyloxy)carbonyl]amino]-3,13-dioxo-1-phenyl-2-oxa-8,9-dithia-4,14-diazahexadecan-16-oic acid | C36H52N6O10S2 | 详情 | 详情 | |
| (VII) | 50622 | (2S)-6-amino-2-[((2S)-2-[[(benzyloxy)carbonyl]amino]-4-sulfanylbutanoyl)amino]hexanoic acid | C18H27N3O5S | 详情 | 详情 | |
| (VIII) | 50623 | (2S)-2-[((2S)-2-[[(benzyloxy)carbonyl]amino]-4-sulfanylbutanoyl)amino]-6-oxohexanoic acid | C18H24N2O6S | 详情 | 详情 | |
| (IX) | 50624 | (2S)-1-((2S)-2-[[(benzyloxy)carbonyl]amino]-4-sulfanylbutanoyl)-6-hydroxy-2-piperidinecarboxylic acid | C18H24N2O6S | 详情 | 详情 | |
| (X) | 50617 | (4S,7S,10aS)-4-[[(benzyloxy)carbonyl]amino]-5-oxooctahydro-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid | C18H22N2O5S | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(V)The treatment of dipeptide S-acetyl-N-(benzyloxycarbonyl)-L-homocysteinyl-L-lysine (I) with L-lysine epsilon aminotransferase (S. paucimobili or E. coli) gives the formyl derivative (II), which is cyclized in acid medium, through the tetrahydropyridinyl intermediate (III), to afford the target pyrido[2,1-b][1,3]thiazepine intermediate (IV). Alternatively, the treatment of dipeptide S-acetyl-N-(benzyloxycarbonyl)-L-homocysteinyl-L-lysine (I) with cell free extracts of E. coli gives N-(benzyloxycarbonyl)-L-homocysteinyl-L-lysine (V), which is digested with L-lysine epsilon aminotransferase (S. paucimobili or E. coli) to yield the formyl derivative (VI). Finally, this compound is cyclized in acid medium to afford the target pyrido[1,2-b][1,3]thiazepine intermediate (IV).
| 【1】 Patel, R.N.; Enzymatic synthesis of chiral intermediates for omapatrilat, an antihypertensive drug. Biomol Eng 2001, 17, 6, 167. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 50625 | (2S)-2-[((2S)-4-(acetylsulfanyl)-2-[[(benzyloxy)carbonyl]amino]butanoyl)amino]-6-aminohexanoic acid | C20H29N3O6S | 详情 | 详情 | |
| (II) | 50626 | (2S)-2-[((2S)-4-(acetylsulfanyl)-2-[[(benzyloxy)carbonyl]amino]butanoyl)amino]-6-oxohexanoic acid | C20H26N2O7S | 详情 | 详情 | |
| (III) | 50627 | (2S)-1-((2S)-4-(acetylsulfanyl)-2-[[(benzyloxy)carbonyl]amino]butanoyl)-1,2,3,4-tetrahydro-2-pyridinecarboxylic acid | C20H24N2O6S | 详情 | 详情 | |
| (IV) | 50617 | (4S,7S,10aS)-4-[[(benzyloxy)carbonyl]amino]-5-oxooctahydro-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid | C18H22N2O5S | 详情 | 详情 | |
| (V) | 50622 | (2S)-6-amino-2-[((2S)-2-[[(benzyloxy)carbonyl]amino]-4-sulfanylbutanoyl)amino]hexanoic acid | C18H27N3O5S | 详情 | 详情 | |
| (VI) | 50623 | (2S)-2-[((2S)-2-[[(benzyloxy)carbonyl]amino]-4-sulfanylbutanoyl)amino]-6-oxohexanoic acid | C18H24N2O6S | 详情 | 详情 |